We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WKL:EURONEXT AMSTERDAMWolters Kluwer N.V. Analysis

Data as of 2026-09-02 - not real-time

€68.06

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Wolters Kluwer N.V. trades at €68.06, with its moving averages tangled rather than clearly stacked — a neutral trend structure. It has gained 13.5% over the past 30 days. With RSI at 51.4 the momentum picture is neutral, alongside a bearish MACD signal. Watch an unavailable price as support and €72.56 as the nearer resistance level.
The shares look undervalued, trading on 11.6 times earnings below a sector average of 28.6. Analyst price targets sit 30.8% above the current price. The 3.67% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With a beta of 0.43 and a maximum drawdown of 100.0%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.

Top Market Events

Wolters Kluwer N.V. has reported first-quarter 2026 results with 4% revenue growth in constant curreWolters Kluwer stock is trading steadily ahead of an early September ex-dividend date, with recent bWolters Kluwer continues its 2026 share repurchase program with fresh transactions reported for June

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 70.23
  • MACD momentum is negative
  • 30-day price change of +13.5%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 11.6 versus sector average of 28.6
  • Trading below the 200-day average of 70.23
  • Analyst targets imply +30.8% versus the current price

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 11.6 versus sector average of 28.6
  • Analyst targets imply +30.8% versus the current price
  • Profit margin of 21.9% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth-0.60%
Profit Margin21.86%
P/E Ratio11.6
ROE146.14%
ROA9.76%
Debt/Equity590.21
P/B Ratio19.3
Op. Cash Flow€1.7B
Free Cash Flow€1.2B
Industry P/E28.6

Technical Analysis

TrendNeutral
RSI51.4
Support€0.00
Resistance€72.56
MA 20€66.44
MA 50€64.03
MA 200€70.23
MACDBearish
VolumeDecreasing
Fear & Greed Index92.04

Valuation

Fair Value€52.92
Target Price€89.03
Upside/Downside30.82%
GradeUndervalued
TypeValue
Dividend Yield3.67%

Risk Assessment

Beta0.43
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.